No description
-
2011 (v1)PublicationUploaded on: March 31, 2023
-
2006 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2009 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2015 (v1)Publication
Introduction: Systemic delivery of bone marrow-derived mesenchymal stem cells (MSC) seems to be of benefit in the treatment of multiple sclerosis (MS), an autoimmune disease of the central nervous system (CNS) sustained by migration of T cells across the brain blood barrier (BBB) and subsequent induction of inflammatory lesions into CNS. MSC...
Uploaded on: April 14, 2023 -
2007 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2009 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2005 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2008 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2005 (v1)Publication
Cyclic ADP-ribose (cADPR) is an intracellular calcium mobilizer generated from NAD(+) by the ADP-ribosyl cyclases CD38 and BST-1. cADPR, both exogenously added and paracrinally produced by a CD38(+) feeder layer, has recently been demonstrated to stimulate the in vitro proliferation of human hemopoietic progenitors (HP) and also the in vivo...
Uploaded on: May 13, 2023 -
2011 (v1)Publication
In several cell types, a regulated efflux of NAD(+) across Connexin 43 hemichannels (Cx43 HC) can occur, and extracellular NAD(+) (NAD(+)(e)) affects cell-specific functions. We studied the capability of bone marrow-derived human mesenchymal stem cells (MSC) to release intracellular NAD(+) through Cx43 HC. NAD(+) efflux, quantified by a...
Uploaded on: April 14, 2023 -
2009 (v1)Publication
Nicotinamide phosphoribosyltransferase (Nampt) inhibitors such as FK866 are potent inhibitors of NAD(+) synthesis that show promise for the treatment of different forms of cancer. Based on Nampt upregulation in activated T lymphocytes and on preliminary reports of lymphopenia in FK866 treated patients, we have investigated FK866 for its...
Uploaded on: October 11, 2023